Duloxetine for Postoperative Analgesia After Modified Radical Mastectomy

Postoperative Analgesia Clinical Trial

Official title:

Duloxetine for Post Operative Analgesia After Modified Radical Mastectomy:A Randomized Controlled Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05442268
• Other study ID #: 35146/12/21
• Status: Recruiting
• Phase: N/A
• Start date: July 16, 2022
• Est. completion date: January 31, 2023

Study information

• Verified date: July 2022
• Source: Tanta University
• Contact: Dina Elfeky, M.B.B.CH.
• Phone: 0 111 747 2680
• Email: dena154452[@]med.tanta.edu.eg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the role of duloxetine in controlling pain after radical mastectomy.

Description:

Inadequate control of postoperative pain is associated with increased length of hospital stay, increased hospital cost, sleep disturbance, depression, functional impairment and affects the quality of life. Modified is one of the commonly performed procedures which is associated with severe postoperative pain. Preemptive analgesia is the analgesic treatment initiated before the surgical procedure to prevent central sensitization from the noxious stimuli. Drugs such as gabapentin, pregabalin, serotonin-norepinephrine reuptake inhibitors, dexamethasone, and cyclooxygenase-2 inhibitors have been used for preemptive analgesia. There are contrary results about the role of duloxetine in mangement of acute postoperative pain. Arecent meta-analysis was done in 2020 that concluded that the currently available evidence does not support the clinical use of duloxetine for the management of acute postoperative pain,so we will discuss that in this study. There are many studies that have shown that perioperative use of duloxetine for a few days has a significant effect on reducing postoperative pain and analgesic requirements. Duloxetine is a dual anti-depressant drug that inhibits the neuronal reuptake of serotonin (5-HT) and norepinephrine (NE) modulating the descending inhibitory pain pathways by increasing the availability of serotonin and norepinephrine. Duloxetine is an approved drug for the treatment of post-traumatic depression, major depression, and generalized anxiety disorder. It is also approved for the treatment of various chronic painful syndromes, including neuropathic pain associated with diabetes, chronic musculoskeletal pain, and fibromyalgia. The mechanisms of action so far described suggest that duloxetine may be useful as an adjunct in the treatment of acute postoperative pain.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: January 31, 2023
• Est. primary completion date: January 31, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Adult female patients aged (18 - 60) years undergoing modified radical mastectomy. American Society of Anesthesiologists Classification I-II-III Exclusion Criteria: Known Allergies to duloxetine.
• Abnormal liver or renal function tests.
• Narrow angle glaucoma.
• Being a chronic opioid abuser (more than 3 months)
• Being on chronic gabapentin or pregabalin (more than 3 months)
• Being on Monoamine oxidase inhibitor, tricyclic antidepressant, or fluvoxamine.
• Pregnant female
• Patients with psychiatric disorders or seizure disorders.

Related Conditions & MeSH terms

• Modified Radical Mastectomy
• Postoperative Analgesia

Intervention

Procedure:
• Acetaminophen group
patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively
• Duloxetine group
Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen every 6 hours postoperatively

Locations

Country	Name	City	State
Egypt	Tanta University hospitals	Tanta	Elgarbia

Sponsors (1)

Lead Sponsor	Collaborator
Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total morphine consumption	Postoperative Total morphine consumption will be recorded	48 hours postoperatively
Secondary	First analgesic request	First analgesic request will be recorded	24 hours postoperatively
Secondary	Post-operative pain	Post-operative pain will be assessed by visual analogue score (VAS) from 0-10 scale 0 (no pain) to 10 (the worst imaginable pain) at 2,4,6 h then every 6h	48 hours postoperatively.
Secondary	Heart rate	Heart rate will be measured every 30 minutes intraoperative and at 0 hour (direct postoperative) at post anesthesia care unit then at 2,4,6 hours at ward then every 6 hours for 48 hours postoperatively	48 hours postoperatively
Secondary	Mean arterial blood pressure	Mean arterial blood pressure will be measured every 30 minutes intraoperative and at 0 hour (direct postoperative) at post anesthesia care unit then at 2,4,6 hours at ward then every 6 hours for 48 hours postoperatively	48 hours postoperatively
Secondary	Adverse effects	Hypotension, Bradycardia, nausea, dry mouth,diarrhea, constipation,insomnia, somnolence, fatigue, hyperhidrosis and pruritus will be observed and treated accordingly	48 hours postoperatively